* Ocugen Inc OCGN.OQ OCGN.O is expected to show no
change in
quarterly revenue when it reports results
*
* Refinitiv's mean analyst estimate for Ocugen Inc is for a
loss
of 7 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 2.2%
in the last three months.
* Wall Street's median 12-month price target for Ocugen Inc
is
$4.5, above its last closing price of $0.37.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 -0.07 -0.07 -0.08 Missed -9.1
Mar. 31 2023 -0.11 -0.11 -0.07 Beat 35.2
Dec. 31 2022 -0.10 -0.10 -0.10 Met -2
Sep. 30 2022 -0.10 -0.10 -0.10 Met -1.7
Jun. -0.08 -0.08 -0.09 Missed -18.4
30 2022
Mar. 31 2022 -0.07 0.00 -0.09 Missed -3,500
Dec. 31 2021 -0.06 -0.06 -0.07 Missed -7.7
Sep. 30 2021 -0.04 -0.04 -0.05 Missed -25
This summary was machine generated November 3 at 19:19 GMT. All
figures in US dollars unless otherwise stated